[[(2R,4S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dimethoxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: [[(2R,4S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dimethoxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• 化学式: C₁₂H₂₀N₅O₁₄P₃
• 分子量: 551.23
• InChiKey: AGZDCCDEVILSGW-DWVWSIQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.5
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  273
• 氢给体数：
  6
• 氢受体数：
  15

文献信息

• ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20150167017A1

  公开（公告）日：2015-06-18

  The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

  本公开提供了替代核苷、核苷酸和核酸以及它们的使用方法。
• MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20150307542A1

  公开（公告）日：2015-10-29

  The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

  本公开提供了修改的核苷酸，核苷酸和核酸，以及使用它们的方法。
• TERMINALLY MODIFIED RNA
  申请人：Chakraborty Tirtha

  公开号：US20140147454A1

  公开（公告）日：2014-05-29

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
• POLYNUCLEOTIDE MOLECULES AND USES THEREOF
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20160264614A1

  公开（公告）日：2016-09-15

  The present disclosure provides alternative nucleosides, nucleotides, and polynucleotides, and methods of use thereof.
• ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20160237134A1

  公开（公告）日：2016-08-18

  The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.